Wednesday, September 28, 2022 6:19:14 PM
imo....thank you Mr. Putin for replying to my communication...we American citizens see through these assholes bs....ty. This is our channel now where you can hear directly from the American market and the American people without interference.... subject to ihub rules....imo JNJ
Huser
Huser
Recent JNJ News
- Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation • PR Newswire (US) • 05/14/2026 08:01:00 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/13/2026 08:29:44 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter • Business Wire • 05/12/2026 11:45:00 AM
- Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference • Business Wire • 05/11/2026 08:34:00 PM
- Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP • PR Newswire (US) • 05/11/2026 12:00:00 PM
- Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission • PR Newswire (US) • 05/07/2026 12:00:00 PM
- Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease • PR Newswire (US) • 05/05/2026 12:05:00 PM
- Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease • PR Newswire (US) • 05/05/2026 12:05:00 PM
- Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System • Business Wire • 05/05/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:58:59 PM
- CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis • PR Newswire (US) • 05/04/2026 12:00:00 PM
- Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations • Business Wire • 04/30/2026 12:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:23:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:21:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:17:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:13:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:12:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:06:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 09:48:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 09:38:22 PM
- Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference • Business Wire • 04/27/2026 08:33:00 PM
